Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
- Conditions
- LeukemiaAmyloidosis
- Interventions
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 25
- Registration Number
- NCT00890552
- Locations
- 🇺🇸
Stanford University Cancer Institute, Stanford, California, United States
Single Dose Steroid Before Thyroidectomy for Benign Disease to Improve Postoperative Nausea, Pain, and Vocal Function
- Conditions
- Postoperative PainPostoperative Nausea and VomitPostoperative Vocal FunctionThyroidectomy
- Interventions
- First Posted Date
- 2009-04-27
- Last Posted Date
- 2012-09-05
- Lead Sponsor
- Ospedale Misericordia e Dolce
- Target Recruit Count
- 80
- Registration Number
- NCT00888303
- Locations
- 🇮🇹
Misericordia and Dolce Hodpital, Prato, Po, Italy
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma
- Conditions
- Advanced Cancer, Various, NOS
- Interventions
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 27
- Registration Number
- NCT00884546
- Locations
- 🇺🇸
City Of Hope National Medical Center, Duarte, California, United States
🇺🇸The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge
- Conditions
- Allergic Conjunctivitis
- Interventions
- First Posted Date
- 2009-04-15
- Last Posted Date
- 2012-03-06
- Lead Sponsor
- Alcon Research
- Registration Number
- NCT00881673
Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy
- Conditions
- Nausea and VomitingUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 430
- Registration Number
- NCT00880191
- Locations
- 🇺🇸
Marshfield Clinic - Weston Center, Weston, Wisconsin, United States
🇺🇸Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States
🇺🇸Illinois CancerCare - Eureka, Eureka, Illinois, United States
Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
- Conditions
- Multiple MyelomaLymphoma, Non-HodgkinSolid Tumors
- Interventions
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2017-10-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 81
- Registration Number
- NCT00871910
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
- Conditions
- Myeloma
- Interventions
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 160
- Registration Number
- NCT00871013
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- S. Maria Hospital, Terni
- Target Recruit Count
- 580
- Registration Number
- NCT00869973
- Locations
- 🇮🇹
Fausto Roila, Terni, Italy
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 90
- Registration Number
- NCT00869232
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)
- Conditions
- Acute Lymphoblastic LeukemiaAdult B Acute Lymphoblastic LeukemiaChildhood B Acute Lymphoblastic Leukemia
- Interventions
- Drug: CyclophosphamideDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: Doxorubicin HydrochlorideOther: Laboratory Biomarker AnalysisDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseDrug: ThioguanineDrug: Vincristine SulfateDrug: PrednisoneRadiation: Prophylactic Cranial Irradiation
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 104
- Registration Number
- NCT00866307
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States
🇺🇸Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.